文献速递冠心病

非ST段抬高型急性冠脉综合征口服P2Y12抑制剂给药时机研究

Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2020-08-31

该随机、适应性、开放标签、多中心试验将1449例非ST段抬高型急性冠脉综合征接受侵入性治疗的患者随机分为上游预处理组(造影前替格瑞洛)和下游未预处理组(PCI时随机替格瑞洛或普拉格雷)。因中期分析无效停止规则试验提前终止,下游与上游策略在30天主要复合终点(血管性死亡、非致死性心梗或卒中、BARC 3/4/5出血)无显著差异(绝对风险降低-0.46%,95%重复置信区间-2.90至1.90)。

要点

  • 下游与上游口服P2Y12抑制剂策略事件率均低且差异极小。
  • 试验因无效提前终止,提示两种策略疗效可能无优劣。
  • PCI亚组(72%人群)及不同造影时机结果一致。

核心结论

  • 下游与上游口服P2Y12抑制剂给药策略在非ST段抬高型急性冠脉综合征接受侵入性治疗患者中事件率低且数值差异极小,试验提前终止提示一种策略优于另一种的可能性不大。

研究设计与样本

  • 随机、适应性、开放标签、多中心临床试验,共随机1449例非ST段抬高型急性冠脉综合征接受侵入性治疗的患者。
  • 患者随机接受造影前替格瑞洛预处理(上游组)或不预处理(下游组),下游组中接受经皮冠状动脉介入治疗者进一步随机接受替格瑞洛或普拉格雷。

主要发现

  • 主要终点为30天内血管性死亡、非致死性心肌梗死或非致死性卒中、以及BARC 3、4、5型出血的复合终点。
  • 下游组与上游组主要终点发生率无显著差异,百分比绝对风险降低为-0.46(95%重复置信区间:-2.90至1.90)。
  • 在接受经皮冠状动脉介入治疗的患者(占人群72%)中以及无论冠状动脉造影时机(入组后24小时内或之后),结果均得到证实。

临床怎么用

  • 对于非ST段抬高型急性冠脉综合征接受侵入性治疗的患者,下游或上游口服P2Y12抑制剂策略均可考虑,两者事件率低且差异极小。

局限性

  • 试验因中期分析无效停止规则而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although oral P2Y12 inhibitors are key in the management of patients with non-ST-segment elevation acute coronary syndrome, the optimal timing of their administration is not well defined. OBJECTIVES: The purpose of this study was to compare downstream and upstream oral P2Y12 inhibitors administration strategies in patients with non-ST-segment elevation acute coronary syndrome undergoing invasive treatment. METHODS: We performed a randomized, adaptive, open-label, multicenter clinical trial. Patients were randomly assigned to receive pre-treatment with ticagrelor before angiography (upstream group) or no pre-treatment (downstream group). Patients in the downstream group undergoing percutaneous coronary intervention were further randomized to receive ticagrelor or prasugrel. The primary hypothesis was the superiority of the downstream versus the upstream strategy on the combination of efficacy and safety events (net clinical benefit). RESULTS: We randomized 1,449 patients to downstream or upstream oral P2Y12 inhibitor administration. A pre-specified stopping rule for futility at interim analysis led the trial to be stopped. The rate of the primary endpoint, a composite of death due to vascular causes; nonfatal myocardial infarction or nonfatal stroke; and Bleeding Academic Research Consortium type 3, 4, and 5 bleeding through day 30, did not differ significantly between the downstream and upstream groups (percent absolute risk reduction: -0.46; 95% repeated confidence interval: -2.90 to 1.90). These results were confirmed among patients undergoing percutaneous coronary intervention (72% of population) and regardless of the timing of coronary angiography (within or after 24 h from enrollment). CONCLUSIONS: Downstream and upstream oral P2Y12 inhibitor administration strategies were associated with low incidence of ischemic and bleeding events and minimal numeric difference of event rates between treatment groups. These findings led to premature interruption of the trial and suggest the unlikelihood of enhanced efficacy of 1 strategy over the other. (Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non-ST Elevated Acute Coronary Syndromes With Initial Invasive Indication [DUBIUS]; NCT02618837).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Tarantini G, Mojoli M, Varbella F, et al. Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2020. PMID: 32882390. doi:10.1016/j.jacc.2020.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。